Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis

N J Cook, G J Carroll

Abstract
Two patients are described with severe and progressive rheumatoid arthritis in whom methotrexate was reintroduced despite previous methotrexate related pneumonitis. In both patients a marked improvement in disease control occurred without a recurrence of the pneumonitis.

In the treatment of severe erosive arthritis, a limited number of disease modifying drugs are available. When all avenues of treatment have led to intolerance or inefficacy in the patient with progressive disease, the question arises as to whether a previously useful but poorly tolerated drug can be safely reintroduced. Factors influencing this decision include the nature of the toxicity previously encountered, the severity of the patient's disease, and the current state of knowledge with respect to the agent in question.

We report here two patients with methotrexate pneumonitis in whom the drug was subsequently reintroduced and in whom pneumonitis did not recur.

Patients and methods
PATIENTS
For the purpose of diagnosis in this study, we used the criteria for methotrexate pneumonitis described by Searles and McKendry.1

METHODS
Gallium-67 scintigraphy was used to monitor the patients during rechallenge with methotrexate. This is a very sensitive but non-specific test for pulmonary inflammation which has been shown to correlate well with other indices of disease activity in inflammatory disorders of the lung, such as sarcoidosis and pulmonary fibrosis.2-4 A 67Ga scan may be abnormal before symptoms develop or before clinical or radiological signs are apparent.5 6

The 67Ga index used was based on the method described by Line et al7; the maximum possible gallium index is 400 U and a scan is considered to be abnormal if the index is greater than 50 U.

Results
PATIENT 1
A 69 year old woman with a 40 year history of rheumatoid arthritis characterised by widespread joint erosion and high concentrations of rheumatoid factor and antinuclear antibodies was treated with methotrexate, 2.5 mg intra-

muscularly once a week, beginning in May 1983, and increasing to 7.5 mg a week over three months. Previous disease modifying drugs included gold salts, cyclophosphamide, sulphalazine, D-penicillamine, azathioprine, and levamisole, all of which had been discontinued because of side effects or lack of efficacy. This patient was unable to tolerate prednisolone. Methotrexate was tolerated and its use was accompanied by marked symptomatic improvement.

In April 1985, she was admitted to her local hospital with a three week history of fever, malaise, dyspnoea, and dry cough. She had never smoked but had a past history of mild asthma controlled by regular use of salbutamol. Examination showed respiratory rate 35/minute, pulse rate 120/minute, blood pressure 140/80 mmHg, temperature 37.8°C (subsequently peaking at 38.1°C). Auscultation showed widespread pulmonary crepitations. A chest radiograph (fig 1) showed diffuse pulmonary infiltrates. Laboratory studies showed a haemoglobin concentration of 111 g/l, white cell count of 4.5 x 10^9/l (neutrophils 76%, lymphocytes 16%, monocytes 8%), and an erythrocyte sedimentation rate of 22 mm/hour. No bacteria were cultured from three sets of blood cultures.

The patient was treated with intravenous ampicillin, gentamicin, and nebulised salbutamol. Her condition deteriorated and she was transferred to an intensive care unit where her arterial blood gas tensions were: PCO₂ 30 mmHg, Po₂ 48 mmHg on 14 l oxygen/min (pH

Figure 1 Chest radiograph of patient 1 on presentation in an erect position.
Successful reintroduction of methotrexate after pneumonitis

7·41, hydrogen carbonate 19 mmol/l, saturation 85%.

A Swan Ganz catheter was inserted and showed low pulmonary artery wedge pressures, excluding pulmonary oedema (pulmonary artery wedge pressure 5 mmHg and pulmonary artery end diastolic pressure 5 mmHg). Blood and sputum cultures were consistently negative, as were serological tests for viral infection, fungal agents, and legionella.

Methotrexate and all other drugs (paracetamol, prochlorperazine, carbamazepine, and salbutamol) were discontinued and intravenous erythromycin, co-trimoxazole, and cefotaxime were given. Ventilation and inotropic support were subsequently required. Antibiotics were discontinued after 11 days.

The patient improved steadily and two weeks after admission her chest radiograph was normal (fig 2). Over the next two years she had no further symptoms of respiratory disease and her chest radiograph remained normal. There was, however, a steady increase in the activity of the synovitis which confined her to bed. In July 1987, at the patient’s request, 2·5 mg of methotrexate was given by mouth once a week. A baseline $^{67}$Ga scan at that time was normal. Since then $^{67}$Ga scans every six months have shown no evidence of recurrent pneumonitis. She is now maintained on a dose of 3·75 mg methotrexate by mouth, alternating with 5 mg weekly. Her synovitis remains under reasonable control and she leads an independent life, mostly in an electric wheelchair.

PATIENT 2

In November 1984 a 66 year old woman with a 14 year history of rheumatoid arthritis characterised by widespread erosive joint destruction and high concentrations of rheumatoid factor and antinuclear antibodies was treated with methotrexate 7·5 mg weekly by mouth. Previous disease modifying drugs included intramuscular gold, D-penicillamine, chlorambucil, and azathioprine, all of which had been discontinued because of inefficacy or adverse side effects. Methotrexate induced clinical remission.

In August 1986 she was admitted with a three week history of cough, increasing shortness of breath, yellow sputum and mouth ulcers. She had never smoked and had no previous history of respiratory disease. In addition to methotrexate she was receiving ibuprofen, folic acid, diazepam, fluoride, calcium supplements, and an antacid. Examination showed a fever of 38-5°C, pulse 120/minute, blood pressure 140/70 mmHg. Examination of the respiratory system showed a respiratory rate of 24/minute and decreased expansion bilaterally, but no added sounds. A chest radiograph showed a longstanding blunting of the costophrenic angles but no interstitial abnormality.

Haematological results showed haemoglobin 85 g/l, white blood cell count 4·1×10$^9$/l, (neutrophils 65%, lymphocytes 8%, monocytes 5%, eosinophils 8%), platelets 123×10$^9$/l. The erythrocyte sedimentation rate was 87 mm/hour. Urea, electrolytes, and liver function tests were normal. No pathogenic bacteria were grown from throat swabs, sputum cultures, and numerous blood cultures, although the patient had received courses of amoxycillin and minocycline prior to admission. All drugs were stopped and in view of the pancytopenia and mouth ulcers folinic acid 25 mg four times a day was given; no further antibiotics were used.

Over the next 12 days there was a swinging fever to a maximum of 39-0°C associated with several episodes of diaphoresis. The mouth ulcers persisted for 10 days, but the cough gradually abated and the dyspnoea improved. The mild pancytopenia resolved. A $^{67}$Ga scan 14 days after admission showed an intense and diffuse increase in uptake, highly suggestive of interstitial lung disease (gallium index, 242; upper limit of normal subjects, 50). Four weeks later she was discharged with minimal residual dyspnoea.

Repeat $^{67}$Ga scans six months and three years later showed an improvement (gallium index 124 and 114, respectively). Respiratory function tests performed at these times were stable and consistent with mild background interstitial lung disease (carbon monoxide transfer factor ($T_{1/CO}$) 14·2 ml/min/mmHg, normal range 18·7-25·9 ml/min/mmHg).

By March 1987 her arthritis had deteriorated considerably. Methotrexate was reintroduced at a dose of 2·5 mg weekly by mouth and increased over one month to 5 mg weekly. Clinical improvement was evident within three months and has been maintained for three years. There has been no recurrence of the symptoms of pneumonitis and regular respiratory function tests and $^{67}$Ga scans have remained stable.

Discussion

Pneumonitis is an uncommon but potentially life threatening complication of treatment with methotrexate. It is not known how often pulmonary toxicity occurs when methotrexate is given to patients with rheumatoid arthritis, but in a retrospective study of 92 patients receiving methotrexate prescribed for malignancy, psoriasis, or connective tissue disease, the incidence was found to be 7-6%. No correlation

Figure 2 Chest radiograph of patient 1 after recovery in a sitting position. Anteroposterior view.
has been shown between pneumonitis and the cumulative dose of methotrexate. Interestingly, pneumonitis has been reported after a total dose of only 12.5 mg methotrexate.  

It is not unusual for methotrexate pneumonitis to resolve without the use of corticosteroid treatment, and although steroids are frequently prescribed there is no convincing evidence that they affect the outcome.  

Clinical recovery from methotrexate pneumonitis is usually complete, as is the resolution of the changes in chest radiographs, but there may be persistent abnormalities in pulmonary function. The death rate from methotrexate pneumonitis is about 10% when the drug is used in non-rheumatological diseases.  

Searles and McKendry described nine criteria for the diagnosis of methotrexate pneumonitis: (a) acute onset of shortness of breath; (b) fever >38°C; (c) tachypnoea ≥28/min and a non-productive cough; (d) radiological evidence of pulmonary interstitial or alveolar infiltrates; (e) white cell count ≤15×10^9/L; (f) negative blood and sputum cultures (obligatory); (g) pulmonary function tests showing restrictive pulmonary function with decreased diffusion capacities; (h) PO2 <55 mmHg on room air at time of admission; and (i) histology consistent with bronchitis or interstitial pneumonitis. They considered that a patient who fulfilled six of the nine criteria had definite pneumonitis, five of nine had probable pneumonitis, and four of nine possible pneumonitis.  

Patient 1 satisfied seven of the nine criteria (acute dyspnoea, fever, dry cough and tachypnoea pulmonary infiltrates, blood leucocyte concentration <15×10^9/L, negative cultures, and arterial hypoxaemia (PO2 <60 mmHg). Accordingly this patient may be classified as definite. Patient 2 satisfied five of the nine criteria (sudden dyspnoea, fever, blood leucocyte concentration <15×10^9/L, and negative cultures). However, the striking scintigraphic evidence of lung inflammation provides additional support for drug related pneumonitis. Furthermore, advancing interstitial lung disease has not been observed during the subsequent three years. We consider that patient 2 should be classified as probable methotrexate pneumonitis, but concede that pulmonary infection may have been responsible. The diagnostic criteria advocated by Searles and McKendry have limitations and in the absence of supportive histopathology it is acknowledged that neither case can be considered proven.  

There are two previous reports describing the outcome of rechallenge with methotrexate after pneumonitis in patients with rheumatoid arthritis. In one report the patient had an atypical presentation with chest pain, cough and dyspnoea. Parainfluenza antibody titres were raised in this patient, casting further doubt on the diagnosis. Nonetheless, no adverse reaction was observed when this patient was rechallenged.  

In the other report three patients were rechallenged. One patient had repeated episodes of respiratory illness each time methotrexate was reinstalled and the diagnosis was eventually made after an open lung biopsy. The other two patients did not develop recurrent pneumonitis after the reintroduction of methotrexate.  

Successful reintroduction of methotrexate after drug related pancytopenia in rheumatoid arthritis has also been described. A large survey is required to identify those patients at particular risk of developing pneumonitis while receiving methotrexate. Until then it is neither practicable nor of established value to perform regular respiratory function tests on all patients receiving methotrexate. Patients who resume methotrexate after pneumonitis are clearly a high risk group and in this situation 67Ga scintigraphy may be a useful adjunct to respiratory function tests for non-invasive surveillance.  

The two patients described here and those reported elsewhere indicate that methotrexate can sometimes be safely reintroduced following pulmonary toxicity in patients with rheumatoid arthritis. However, reports of recurrent pneumonitis on rechallenge emphasise that this is not always possible and caution is therefore recommended.  

We thank Dr E T Owen for permission to report on his patient and for his helpful comments. We also thank Ms A Dalgarino for her secretarial services.

Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis.

N J Cook and G J Carroll

doi: 10.1136/ard.51.2.272